218 related articles for article (PubMed ID: 8263505)
1. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.
Neyts J; De Clercq E
J Med Virol; 1993 Nov; 41(3):242-6. PubMed ID: 8263505
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
Neyts J; Sobis H; Snoeck R; Vandeputte M; De Clercq E
Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):269-79. PubMed ID: 8390357
[TBL] [Abstract][Full Text] [Related]
3. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
Smee DF; Bailey KW; Wong MH; Sidwell RW
Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
[TBL] [Abstract][Full Text] [Related]
4. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice.
Smee DF; Bailey KW; Sidwell RW
Chemotherapy; 2003 Jun; 49(3):126-31. PubMed ID: 12815205
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
Quenelle DC; Collins DJ; Kern ER
Antimicrob Agents Chemother; 2003 Oct; 47(10):3275-80. PubMed ID: 14506041
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice.
Neyts J; Balzarini J; Naesens L; De Clercq E
J Med Virol; 1992 May; 37(1):67-71. PubMed ID: 1320099
[TBL] [Abstract][Full Text] [Related]
8. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.
Quenelle DC; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Kern ER
Antimicrob Agents Chemother; 2004 Feb; 48(2):404-12. PubMed ID: 14742188
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections.
De Clercq E
Verh K Acad Geneeskd Belg; 1996; 58(1):19-47; discussion 47-9. PubMed ID: 8701600
[TBL] [Abstract][Full Text] [Related]
10. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Li SB; Yang ZH; Feng JS; Fong CK; Lucia HL; Hsiung GD
Antiviral Res; 1990 May; 13(5):237-52. PubMed ID: 2168690
[TBL] [Abstract][Full Text] [Related]
11. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir.
Smee DF; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2001 Jan; 12(1):71-6. PubMed ID: 11437324
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
Quenelle DC; Collins DJ; Kern ER
Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
[TBL] [Abstract][Full Text] [Related]
13. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice.
Smee DF; Bailey KW; Wong MH; Wandersee MK; Sidwell RW
J Infect Dis; 2004 Sep; 190(6):1132-9. PubMed ID: 15319864
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice.
De Clercq E; Holý A
Antimicrob Agents Chemother; 1991 Apr; 35(4):701-6. PubMed ID: 2069375
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Stals FS; de Clercq E; Bruggeman CA
Antimicrob Agents Chemother; 1991 Nov; 35(11):2262-6. PubMed ID: 1666493
[TBL] [Abstract][Full Text] [Related]
16. Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.
Neyts J; Snoeck R; Balzarini J; De Clercq E
Antiviral Res; 1991 Jul; 16(1):41-52. PubMed ID: 1663729
[TBL] [Abstract][Full Text] [Related]
17. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia.
Neyts J; Leyssen P; Verbeken E; De Clercq E
Antimicrob Agents Chemother; 2004 Jun; 48(6):2267-73. PubMed ID: 15155231
[TBL] [Abstract][Full Text] [Related]
19. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
Smee DF; Bailey KW; Wong MH; Tarbet EB
Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (orthopoxvirus) infections in mice.
Neyts J; De Clercq E
Antimicrob Agents Chemother; 2001 Jan; 45(1):84-7. PubMed ID: 11120949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
